The forecast for Genito Urinary System and Sex Hormones sales in Canada from 2024 to 2028 shows a gradual decline, with per capita values starting at $30.4 in 2024 and dropping to $29.8 by 2028. Comparing to 2023, the year-on-year changes from 2024 onwards indicate a fluctuating declining trend, with minor percentage decreases annually. Through this period, the Compound Annual Growth Rate (CAGR) suggests a modest average reduction in sales per year.
Future trends to watch for include potential changes in healthcare policies, innovations in pharmaceutical products, and shifting demographic patterns. These factors could impact the sales trajectory, either accelerating the decline or stabilizing the demand for these products.
